Request Demo

Last update 05 Sep 2025

Teplizumab

Last update 05 Sep 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

hOKT3-gamma-1-ala-ala, hOKT3-γ1-ala-ala, Teplizumab (USAN/INN)

+ [6]

Target

CD3

Action

inhibitors

Mechanism

CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors)

Therapeutic Areas

Immune System DiseasesEndocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Inactive Indication

Chronic large plaque psoriasisGlucose Intolerance

Originator Organization

MacroGenics, Inc.

Active Organization

Aventis Pharma Ltd.

Eli Lilly & Co.Sanofi-Aventis Recherche & Développement SA

+ [5]

Inactive Organization

MacroGenics, Inc.

National Institute of Diabetes & Digestive & Kidney Diseases

License Organization

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (17 Nov 2022),

Diabetes Mellitus, Type 1

RegulationPriority Review (United States), Breakthrough Therapy (United States), PRIME (European Union), Priority Review (China)

Structure/Sequence

Sequence Code 9717228L

Source: *****

Sequence Code 9976075H

Source: *****

Clinical Trials associated with Teplizumab

NCT07088068

/ RecruitingPhase 3

A Randomized, Double-blind, 2-arm, Phase 3 Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Newly Diagnosed Stage 3 Type 1 Diabetes (T1D)

This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment.
The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenous (IV) infusion, in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) aged 1 to 25 years, on standard insulin therapy.

Start Date06 Aug 2025

Sponsor / Collaborator

Sanofi

NCT06791291

/ RecruitingPhase 2

Efficacy and Safety of Teplizumab in the Treatment of Japanese Pediatric and Adult Participants Aged 8 to 34 Years With Stage 2 Type 1 Diabetes: A Multicenter, Randomized, Open-label, Controlled Study.

This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment.
Teplizumab has been approved by FDA to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. The dose regimen of teplizumab in this study is consistent with the regimen approved by US FDA.
Given prior clinical studies conducted in Western countries, this design is appropriate to assess the efficacy, safety and tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of a 14-day IV infusion regimen of teplizumab in Japanese Stage 2 T1D participants aged 8 to 34 years.

Start Date25 Jul 2025

Sponsor / Collaborator

Sanofi

NCT06892002

/ CompletedNot Applicable

A Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated With Teplizumab

Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms; most patients with Stage 3 T1D meet standard diagnostic criteria for diabetes and require insulin treatment.
Teplizumab has been shown to delay progression to Stage 3 in participants at Stage 2 in a Phase 2 clinical trial, leading to subsequent approval in the United States of America (USA). Patients outside of the USA are able to receive the treatment through Pre-Registration Import Licenses and Managed Access Programs. The current study will collect data on the use of teplizumab in routine care, to better understand which patients received teplizumab and how these patients were managed after they received the treatment.

Start Date11 Feb 2025

Sponsor / Collaborator

Sanofi

100 Clinical Results associated with Teplizumab

100 Translational Medicine associated with Teplizumab

100 Patents (Medical) associated with Teplizumab

613

Literatures (Medical) associated with Teplizumab

01 Oct 2025·JOURNAL OF DIABETES AND ITS COMPLICATIONS

What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?

Review

Author: Wilson, Maria Aurora Roma ; Pozzilli, Paolo

Type 1 diabetes (T1D) is a heterogeneous autoimmune disease with multiple endotypes, each demonstrating distinct clinical and immunological characteristics. Teplizumab, an anti-CD3 monoclonal antibody, has emerged as a promising immunomodulatory therapy capable of delaying the progression of T1D in individuals with stage 2 disease. However, variability in therapeutic response suggests that certain endotypes may derive greater benefit from treatment. This review evaluates the suitability of different T1D endotypes (T1DE) for teplizumab prevention trials, with a particular focus on early-onset T1DE1 and T1DE2. Clinical trials demonstrate that individuals under 15 years of age, who demonstrate the highest immune activity, marked by aggressive T-cell infiltration and rapid pancreatic β-cell destruction, experience the most significant delay in disease progression following teplizumab treatment, highlighting the importance of early intervention. Furthermore, shifting individuals from the rapidly progressing T1DE1 trajectory to the more gradual T1DE2 course may extend functional insulin production and improve long-term metabolic outcomes. This paper underscores the need for expanded endotype-specific prevention trials and optimised screening protocols to identify high-risk individuals at the earliest stage. Future research should explore teplizumab's efficacy in younger populations and refine predictive biomarkers to enhance personalised intervention strategies in T1D management.

07 Aug 2025·JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Challenges and Opportunities for Understanding the Pathogenesis of Type 1 Diabetes: An Endocrine Society Scientific Statement

Review

Author: Brusko, Todd M ; Michels, Aaron W ; Richardson, Sarah J ; Evans-Molina, Carmella ; Homann, Dirk ; Powers, Alvin C

Abstract:

The discovery of insulin transformed type 1 diabetes (T1D) from a lethal disease to a chronic health condition where individuals can lead long and productive lives. However, T1D is still associated with considerable morbidity and mortality, underscoring the need for disease-modifying therapies to delay clinical onset and preserve residual pancreatic β-cell function in those newly diagnosed with T1D. Notably, the first disease-modifying therapy (teplizumab, a monoclonal antibody targeting CD3+ on T lymphocytes) was approved by the US Food and Drug Administration in November 2022 to delay the clinical onset of T1D, thus opening new avenues to treat T1D as an immunologic disease rather than simply as a metabolic disease with lifelong insulin administration. In this Scientific Statement, we will integrate and summarize information about the pathogenesis of T1D, highlight gaps in current knowledge, and propose future activities that may lead to additional approaches to treat the underlying autoimmunity and β-cell defects in diabetes. Hopefully, these efforts, when combined with other rapidly improving T1D therapeutics including automated insulin delivery and cell replacement therapy, will lead to better long-term outcomes for those living with T1D.

05 Aug 2025·Sexual Medicine

Identifying therapeutic targets for erectile dysfunction in the European population using genome-wide Mendelian randomization

Article

Author: Liu, Qiusong ; Lin, Junwei ; Guo, Peng ; Zhang, Hongjian ; Cao, Rong ; Guo, Huan ; Pan, Heng ; Wan, Zheng ; Zhou, Xu

Abstract:

Background:

Erectile dysfunction (ED) is a prevalent condition with current treatments limited by suboptimal efficacy and adverse effects. Mendelian randomization (MR) offers a promising approach to identify potential genetic targets for novel therapies.

Aim:

We performed a genome-wide MR study on druggable genes to find ED therapies.

Methods:

We collected data on drug-targetable genes and their impact on blood expression quantitative trait loci (eQTLs). Using two-sample MR with genome-wide association studies data, we pinpointed genes linked to ED and conducted enrichment analysis. We also built protein networks and predicted drugs to support treatment development.

Outcomes:

This comprehensive strategy provides a robust framework for the advancement of more efficacious and precisely targeted treatments for ED.

Results:

The MR analysis identified 124 genes significantly associated with ED. Enrichment analysis revealed these genes are involved in signal transduction, protein phosphorylation, plasma membrane, cytoplasm, ATP binding, and the PI3K-Akt signaling pathway. We identified the top 10 hub genes: PRKCA, IFNG, ITGB1, PPARG, PTK2, LAMA5, BCL2L1, CD3D, CD3E, and CD27. Our study highlighted three potential drugs targeting three of these hub genes: benztropine for CD27, teplizumab for CD3E, and natalizumab for ITGB1.

Clinical Translation:

The study identifies high-priority targets for ED therapy, including approved drugs amenable to rapid repurposing trials.

Strengths and Limitations:

Multi-omics integration enhanced causal validity; drug predictions leveraged existing therapeutic knowledge. Tissue-specific expression quantitative trait loci confounders and lack of experimental validation for prioritized drugs require caution.

Conclusion:

This work advances ED research by mapping druggable genes (PRKCA, IFNG, ITGB1) and pathways via MR, offering precision medicine opportunities and actionable drug repurposing candidates.

170

News (Medical) associated with Teplizumab

22 May 2025

·www.prnewswire.com

Laureate Announced for Hamm International Prize for Diabetes Research

Honoree has made outstanding contributions toward understanding the pathogenesis and prevention of Type 1 diabetes OKLAHOMA CITY, May 22, 2025 /PRNewswire/ -- The prestigious Harold Hamm International Prize for Biomedical Research in Diabetes, an honor bestowed by OU Health Harold Hamm Diabetes Center at the University of Oklahoma Health Sciences, will be awarded this fall to Professor Dr. Anette-Gabriele Ziegler, Director of the Institute of Diabetes Research, Helmholtz Munich, German Research Center for Environmental Health. She is also Chair in Diabetes and Gestational Diabetes at Technische Universität München, School of Medicine. She is being honored for her research to understand the pathogenesis of Type 1 diabetes and efforts toward its prediction, early diagnosis and prevention. Continue Reading Professor Dr. Anette-Gabriele Ziegler, director of the Institute of Diabetes Research at the Helmholtz Munich, German Research Center for Environmental Health, has been selected as the 2025 recipient of the prestigious OU Health Herald Hamm Diabetes Center's Harold Hamm International Prize for Biomedical Research in Diabetes. The Hamm Prize recognizes and encourages lasting advances in research related to Type 1 or Type 2 diabetes. It is awarded to an individual who has either demonstrated lifelong contributions to the field or realized a singular advance, especially one that promotes curative potential. The honor includes a $250,000 award, the largest of its kind in the world. It was established to recognize and promote lasting achievements in diabetes research focused on progress toward a cure. "The award is an incredible motivation to look ahead and continue on the path toward understanding the pathogenesis of Type 1 diabetes and developing preventive therapies – with the ultimate goal of finding a cure," Ziegler said. The prize, established in 2012, is named for Harold Hamm, chairman and chief executive officer of Oklahoma-based Continental Resources Inc., who provided an endowment to fund the prize in perpetuity. The Hamm Prize laureate is selected by a rotating jury of national and international leaders in the diabetes research community and is awarded every two years. "This prize honors work that changes the course of science – and Dr. Ziegler's research does exactly that. Her leadership in uncovering how Type 1 diabetes begins and how we might stop it before it starts is the kind of bold, life-changing progress this prize was meant to recognize. Her work fuels our hope – and brings us all one step closer to the cure," Hamm said. Ziegler's research has been at the forefront of translating important research questions into longitudinal studies, including more than 20 clinical trials, as well as implementing findings into public health. Her achievements include: Launched BabyDiab, the first birth cohort to study when and how Type 1 diabetes begins. Launched Fr1da, a public screening program to detect early signs of Type 1 diabetes, now a model for similar global efforts. Initiated and serves as speaker of GPPAD (Global Platform for the Prevention of Autoimmune Diabetes), a European platform to translate knowledge about disease pathogenesis into trials seeking to prevent Type 1 diabetes. More than 2,000 infants have been enrolled in GPPAD's clinical trials and screened for genetic risk of Type 1 diabetes. Conducted research that led to a landmark clinical trial resulting in Food and Drug Administration approval for teplizumab, the first immunotherapy drug shown to delay the onset of Type 1 diabetes in at-risk individuals. In addition, Ziegler has made the following research discoveries: Autoimmunity to insulin is a key starting point for Type 1 diabetes in children, and Type 1 diabetes susceptibility genes predispose for autoimmunity. Islet autoimmunity (when the immune system mistakenly attacks and destroys insulin-producing cells in the pancreas) starts early in life, with a peak incidence around age 1 to 2. Children with two or more islet autoantibodies almost always develop diabetes. Respiratory viral infections in early life, including COVID-19, raise the risk of islet autoimmunity in genetically at-risk children. Early changes in blood sugar and immune activity appear to precede the onset of autoimmunity to insulin. A physician who conducts research, Ziegler said caring for patients has informed her career as a scientist. "My mentor always used to say, 'A researcher is the best doctor,'" she said. "I'm not sure if the reverse is true, but my daily work with people living with diabetes and my experience as a physician have certainly shaped my research. They have especially influenced my strong focus on translational research, clinical trials, and investigating the origins of the disease in humans." Ziegler will receive the Hamm Prize during a gala in October. Jed Friedman, Ph.D., director of Harold Hamm Diabetes Center, said Ziegler's distinguished research career has significantly advanced the aim of preventing Type 1 diabetes. "Professor Dr. Ziegler's visionary leadership and unwavering commitment have not only advanced scientific understanding but also paved the way for novel interventions that improve patient outcomes by delaying the onset of Type 1 diabetes," Friedman said. "Her work exemplifies the integration of rigorous research with compassionate clinical application, embodying the highest ideals of medical science. We are privileged to honor [her] for her unparalleled contributions to diabetes research and her enduring impact on public health." About the project For more information about the Harold Hamm International Prize for Biomedical Research in Diabetes, visit the prize website here. About the University of Oklahoma Founded in 1890, the University of Oklahoma is a public research university with campuses in Norman, Oklahoma City and Tulsa. As the state's flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. In Oklahoma City, OU Health Sciences is one of the nation's few academic health centers with seven health profession colleges located on the same campus. OU Health Sciences serves approximately 4,000 students in more than 70 undergraduate and graduate degree programs spanning Oklahoma City and Tulsa and is the leading research institution in Oklahoma. For more information about OU Health Sciences, visit . SOURCE University of Oklahoma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical StudyImmunotherapy

14 Mar 2025

·www.globenewswire.com

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange. Tiziana was previously notified by Nasdaq on January 29, 2025 that it was not in compliance with the minimum bid-price listing rule (under Rule 5550(a)(2)) because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least ten consecutive trading days which was met on March 12, 2025. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and this matter is now closed. The Company’s securities will continue to be listed and traded on The Nasdaq Stock Market. About Foralumab Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. The FDA has recently allowed an additional 20 patients to be enrolled in this EA program. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923). Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development, binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been observed in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2] About Tiziana Life Sciences Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications. For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com. For further inquiries: Tiziana Life Sciences LtdPaul Spencer, Business Development, and Investor Relations+44 (0) 207 495 2379email: info@tizianalifesciences.com [1] https://www.pnas.org/doi/10.1073/pnas.2220272120[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

ImmunotherapyPhase 2

31 Dec 2024

·www.echemi.com

7 New Drugs Expected to Be Approved in 2025

In 2024, China approved several new drugs, and more blockbuster drugs are expected to be launched in 2025, covering oncology, autoimmune diseases, rare diseases, and other therapeutic areas. Drug Name Mechanism of Action Indications Development Institutions Evantuzumab c-Met/EGFR bispecific antibody Non-small cell lung cancer Johnson & Johnson; Genmab Taqetuzumab CD3/GPRC5D bispecific antibody Multiple myeloma Johnson & Johnson; Genmab Zenidatuzumab Anti-HER2 bispecific antibody Biliary tract cancer Zymeworks; Jazz Pharmaceuticals; BeiGene Inalises PI3Kα inhibitor HR-positive breast cancer Roche; Chugai Pharmaceutical Asunitinib STAMP allosteric inhibitor Speculated use for chronic myeloid leukemia treatment Novartis Tazemetostat EZH2 inhibitor Follicular lymphoma Epizyme; Huadong Medicine; Eisai Relatuzumab-alpha PDL1/TGF-β bispecific antibody Stomach cancer; gastroesophageal junction cancer Hengrui Medicine; Dong-A Pharma Vabysmo EGFR antibody-drug conjugate Nasopharyngeal cancer Lepu Biopharma Tenapanor NHE3 inhibitor Chronic kidney disease hyperphosphatemia Ardelyx; Kyowa Kirin; Fosun Pharma; AstraZeneca Mersutide OXM analog; GLP-1R/GCGR agonist Obesity Eli Lilly; Innovent Biologics Vusirumab IL-1β monoclonal antibody Gouty arthritis Junshi Biosciences Romosozumab SOST monoclonal antibody Osteoporosis Astellas; Amgen; UCB Teplizumab CD3 monoclonal antibody Type 1 diabetes Ligand Pharmaceuticals; Johnson & Johnson; Sanofi Solrepinib Syk inhibitor Immune thrombocytopenic purpura Huadong Medicine BBM-H901 Factor IX gene therapy Hemophilia B Gene Therapy Fitusiran RNAi therapy Hemophilia A; Hemophilia B Sanofi; Alnylam Andexanet alfa Recombinant factor Xa Factor Xa inhibitor antidote Portola Pharmaceuticals Lisocabtagene maraleucel IL-23p19 monoclonal antibody Crohn's disease Boehringer Ingelheim; AbbVie Lemborexant & Daridorexant OX1R antagonist; OX2R antagonist Insomnia Eisai & Idorsia; Sihuan Pharmaceutical; Nxera Pharma Highlights of new drug approvals in 2024 include: 1. Oncology: The world’s first antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) for ovarian cancer: Mirvetuximab soravtansine. PD-1/VEGF bispecific antibody envafolimab and Nectin-4 ADC enfortumab vedotin. 2. Autoimmune diseases: IL-17A/F monoclonal antibody bimekizumab for ankylosing spondylitis. 3. Rare diseases: Novartis’ complement factor B inhibitor for paroxysmal nocturnal hemoglobinuria (PNH). Blockbuster drugs expected to be approved in 2025 include: Oncology: Amivantamab (Q1) The world’s first c-Met/EGFR bispecific antibody. Highlight: Phase III study showed significant extension of median progression-free survival (mPFS). Talquetamab (Q2) A CD3/GPRC5D bispecific antibody and the world’s first drug targeting GPRC5D. Clinical results: Objective response rate (ORR) in Chinese patients was 69.0%-73.6%. Zanidatamab (Q2) A HER2-targeting bispecific antibody based on Azymetric™ technology. Indication: HER2-positive biliary tract cancer (BTC) with an ORR of up to 52%. Inavolisib (Q3) Roche’s highly selective PI3Kα inhibitor for PIK3CA-mutated breast cancer. Asciminib (Q3) Novartis’ Bcr-Abl allosteric inhibitor for Philadelphia chromosome-positive chronic myeloid leukemia (CML). SHR-1701 (Q4) A PD-L1/TGF-βRII bifunctional fusion protein for first-line treatment of gastric cancer. Phase III study demonstrated significant extension in median overall survival. MRG003 (Q4) China’s first EGFR-targeting ADC with remarkable efficacy in nasopharyngeal carcinoma. Endocrinology and Metabolism: Tenapanor (Q1) The world’s only approved NHE3 inhibitor for controlling hyperphosphatemia in chronic kidney disease patients. Trend Analysis: Continued Innovation in Oncology: The emergence of multiple bispecific antibodies and ADC drugs is making targets and treatment options more precise and diverse. Breakthroughs in Autoimmune and Rare Diseases: New biologics are gradually addressing drug resistance and limited treatment options in previous therapies. Emergence of Domestic Innovative Drugs: Examples include SHR-1701 and MRG003, highlighting the growing research and development capabilities of Chinese pharmaceutical companies. The sequential launch of these drugs will provide new therapeutic options for Chinese patients and enhance China’s position in the global pharmaceutical market.

Drug ApprovalPhase 3Clinical ResultADCImmunotherapy

100 Deals associated with Teplizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D09013	Teplizumab	-	DB06606

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	United States	Provention Bio, Inc.	17 Nov 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 2	United States	National Institute of Diabetes & Digestive & Kidney Diseases	01 Aug 2010
Glucose Intolerance	Phase 2	Canada	National Institute of Diabetes & Digestive & Kidney Diseases	01 Aug 2010
Glucose Intolerance	Phase 2	Germany	National Institute of Diabetes & Digestive & Kidney Diseases	01 Aug 2010
Chronic large plaque psoriasis	Phase 2	United States	MacroGenics, Inc.	01 Dec 2009
Chronic large plaque psoriasis	Phase 2	United States	Eli Lilly & Co.	01 Dec 2009
Diabetes Mellitus, Type 2	Clinical	United States	Sanofi	27 Sep 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


TN-10 Extension (ADA2025)	Phase 2	Diabetes Mellitus, Type 1	6	Teplizumab	xvmaaviwnx(hhnpdwbtxs) = hffbmcovke hooymohluu (cjzdxpysnl, 0.209) View more	Positive	20 Jun 2025
NCT04270942 (CTgov)	Phase 2	Diabetes Mellitus, Type 1	6	Teplizumab	gqimsibfqk = lcltmbnikv eaxsioidgr (kcnodnnapn, yiyflqobnl - tnoqdtokkj) View more	-	12 Feb 2025
NCT01030861 (Pubmed \| J Clin Invest)	Phase 2	Diabetes Mellitus, Type 1	-	Teplizumab	xrokhzajxk(qpbtgmpbha) = reduced with teplizumab treatment usblfamwag (srxcrqakku ) View more	Positive	13 Aug 2024
NCT03875729 (PROTECT, ADA2024) Manual	Phase 3	Diabetes Mellitus, Type 1	275	Teplizumab	tuniberubq(fertfbuccv) = rsiwscooio kxhflwnshe (cfprjyfrsb, -2.27 to -1.87) View more	Positive	20 Jun 2024
				Placebo	tuniberubq(fertfbuccv) = suamqpgiyz kxhflwnshe (cfprjyfrsb, -1.94 to -1.67) View more
ADA2024	Not Applicable	Diabetes Mellitus, Type 1	-	Teplizumab	ncwznvxbaq(vycxrgknlr) = No participants with an AE of COVID-19 were hospitalized or received antiviral treatment cinbbrrylw (lsmfznkamw ) View more	-	14 Jun 2024
				Placebo
NCT03875729 (PROTECT, CTgov)	Phase 3	Diabetes Mellitus, Type 1	328	Placebo (Placebo)	xajnwttplb(zsguvscmnd) = bxmqyvuvki mncsgviych (witigvdonv, rjomyjyhyg - lkfxbjfyxu) View more	-	24 Apr 2024
				teplizumab (Teplizumab)	xajnwttplb(zsguvscmnd) = tpqunrwyun mncsgviych (witigvdonv, qkqfuyexub - fhifcqolng) View more
NCT00920582 (CTgov)	Phase 3	Diabetes Mellitus, Type 1	254	Teplizumab Herold Regimen (Herold Regimen)	dtokmhbpsc = mxmlurrecf godlytfllx (evdooyktcm, tcdwsdpput - rysvtbuxfw) View more	-	20 Dec 2023
				Teplizumab 33.3% Herold Regimen (33.3% Herold Regimen)	dtokmhbpsc = niiyjlhytm godlytfllx (evdooyktcm, mfcbchmugi - ixexskkwns) View more
NCT00385697 (Protégé Study, CTgov)	Phase 2/3	Diabetes Mellitus, Type 1	554	Teplizumab (Open-label Herold Regimen)	lmwqyywfxw = gixyegsgat dkxbbvxzan (xwlaqeuicp, snyehmjsgw - lwncsgxamy) View more	-	05 Dec 2023
				Teplizumab (Double-blind Herold Regimen)	ipxgnvlfoh = jbhuotcpdh diwuykzbwy (bxnexezwcq, etjseiramf - cqktiattje) View more
NCT03875729 (PROTECT, Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 3	Diabetes Mellitus, Type 1	-	Teplizumab	deolqcpkgd(agfustopjl) = Patients treated with teplizumab (217 patients) had significantly higher stimulated C-peptide levels than patients receiving placebo (111 patients) at week 78 (least-squares mean difference, 0.13 pmol per milliliter; 95% confidence interval [CI], 0.09 to 0.17; P<0.001), and 94.9% (95% CI, 89.5 to 97.6) of patients treated with teplizumab maintained a clinically meaningful peak C-peptide level of 0.2 pmol per milliliter or greater, as compared with 79.2% (95% CI, 67.7 to 87.4) of those receiving placebo. xkwxsbuuax (hymijoepze ) View more	Positive	18 Oct 2023
				placebo
NCT03751007 (Phase 1b/2a, EASD2021)	Phase 1/2	Diabetes Mellitus, Type 1 C-peptide \| preproinsulin (PPI)-	-	AG019 monotherapy	krbqcpngsx(xbnzurdpgp) = AG019 was well tolerated and safe when administered for 8 weeks as monotherapy or in association with teplizumab. No serious adverse events and no AG019 treatment discontinuation occurred due to TEAEs. Most TEAEs reported were mild (72.3%) and sometimes moderate (24.3%). AG019 safety profile was similar between adults and adolescents and there was no evidence of dose-related TEAEs. The safety profile of teplizumab in association with AG019 was consistent with that of teplizumab. vzegeijkgc (zypfiatuti ) View more	Positive	01 Oct 2021
				AG019/teplizumab combination therapy

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis